药石科技(300725) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 383,440,937.44, representing a 14.24% increase compared to CNY 335,643,580.55 in the same period last year[6] - Net profit attributable to shareholders decreased by 18.47% to CNY 57,755,969.84 from CNY 70,839,845.23 year-on-year[6] - The basic earnings per share fell by 19.44% to CNY 0.29 from CNY 0.36 in the same period last year[6] - Net profit for Q1 2023 was ¥57,755,961.44, a decrease of 22.3% from ¥74,367,424.72 in Q1 2022[24] - The total comprehensive income attributable to the parent company was CNY 56,506,003.88, a decrease from CNY 70,600,622.80 in the previous period, representing a decline of approximately 19.99%[25] Cash Flow - The net cash flow from operating activities surged by 277.85% to CNY 75,015,353.97, up from CNY 19,853,090.75 in the previous year[6] - The net cash flow from operating activities was CNY 75,015,353.97, significantly up from CNY 19,853,090.75 in the previous period, indicating an increase of approximately 276.56%[28] - The total cash inflow from investment activities was CNY 119,249,255.06, down from CNY 771,161,653.00 in the previous period, reflecting a decrease of about 84.54%[28] - The net cash flow from financing activities was CNY 160,009,193.27, compared to CNY 152,081,619.07 in the previous period, showing an increase of approximately 5.87%[28] - The total cash and cash equivalents at the end of the period were CNY 820,190,549.66, compared to CNY 691,525,233.54 at the end of the previous period, an increase of approximately 18.61%[28] Assets and Liabilities - The company's total assets grew by 2.93% to CNY 5,004,414,338.77 from CNY 4,862,189,119.46 at the end of the previous year[6] - Current liabilities totaled ¥757,364,339.56, a slight increase from ¥739,178,415.06 in the previous year[22] - Long-term borrowings increased to ¥396,740,667.16, compared to ¥346,740,667.16 in Q1 2022, reflecting a growth of 14.4%[22] - The equity attributable to shareholders of the parent company rose to ¥2,721,037,027.73, compared to ¥2,657,635,982.95 in the previous year[22] Research and Development - Research and development expenses increased by 75.81% to CNY 48,393,224.73, compared to CNY 27,526,324.50 in the same period last year[10] - Research and development expenses rose to ¥48,393,224.73, a significant increase of 75.7% compared to ¥27,526,324.50 in the same period last year[24] Revenue Segments - The CDMO segment contributed ¥294,454,899.25, accounting for 76.79% of total revenue, with a year-on-year growth of 15.50%[18] - The company’s revenue from molecular building blocks was ¥87,016,896.24, which is 22.69% of total revenue, showing an 11.55% increase year-on-year[18] - The company’s other revenue segment saw a decline of 26.89% year-on-year, totaling ¥1,969,141.95[18] Shareholder Information - The top shareholder, Yang Minmin, holds 20.69% of the shares, with 30,980,264 shares pledged[16] - The total number of common stock shareholders at the end of the reporting period was 28,597[13] - The total number of restricted shares at the end of the period was 31,211,339, with no new restrictions added during the period[16] Operational Metrics - The company reported a gross profit margin of approximately 45.5% for Q1 2023, down from 52.2% in Q1 2022[24] - Total operating costs increased to ¥344,985,836.29, up 35.5% from ¥254,700,510.42 in the previous year[23] - The company reported a significant increase in cash received from tax refunds, which rose by 78.48% to CNY 29,222,569.06 from CNY 16,372,641.23 year-on-year[10] - The company experienced a decrease in cash flow from investment activities, with cash recovered from investments dropping by 85.46% to CNY 111,529,536.99 from CNY 767,284,122.10 in the previous year[11] - The company did not conduct any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[25]